PIKFYVE inhibitors have therapeutic potential to eliminate PIKFYVE-dependent cancer cells, such as those in some melanoma [22] and colorectal cancers [10], as well as pluripotent cancer stem cells, such those derived from teratocarcinomas [11]. This evidence concerns the gene PIKFYVE and melanoma.